Videos and webinars

1. Allogeneic vs. Autologous MSCs And The Challenge Of Scale 10/2/2026

   During this segment of Cell & Gene Live, Scaling Next-Gen MSC Therapies Without Scaling Risk, Miguel Forte, M.D., Ph.D., CEO and Co-Founder, Kiji Therapeutics, Michael Schuster, Director of Business Development, Mesoblast, and Edward Ahn, Ph.D., CEO and Director, MEDIPOST Inc. compare allogeneic and autologous approaches, including donor variability, dose, point-of-care considerations and why expansion becomes an important factor when developing MSC therapies for commercial-scale use.

2. Why Clinical Trial Design Matters For MSC Success 10/2/2026

   During this segment of Cell & Gene Live, Scaling Next-Gen MSC Therapies Without Scaling Risk, Miguel Forte, M.D., Ph.D., CEO and Co-Founder, Kiji Therapeutics, Michael Schuster, Director of Business Development, Mesoblast, and Edward Ahn, Ph.D., CEO and Director, MEDIPOST Inc. share how recent negative iPSC-derived MSC clinical data should be interpreted, including the potential impact of trial design, patient selection, dosing and the challenges of demonstrating efficacy in difficult indications.

3. How Manufacturing Changes Can Create Risk For MSCs 10/2/2026

   In this segment of Cell & Gene Live, Scaling Next-Gen MSC Therapies Without Scaling Risk, Miguel Forte, M.D., Ph.D., CEO and Co-Founder, Kiji Therapeutics, Michael Schuster, Director of Business Development, Mesoblast, and Edward Ahn, Ph.D., CEO and Director, MEDIPOST Inc. address the transition from early development into larger-scale manufacturing and why process changes can introduce biological and comparability risks.

4. Uncovering The Biggest Risk In Scaling MSCs 10/2/2026

   In this segment of Cell & Gene Live, Scaling Next-Gen MSC Therapies Without Scaling Risk, Miguel Forte, M.D., Ph.D., CEO and Co-Founder, Kiji Therapeutics, Michael Schuster, Director of Business Development, Mesoblast, and Edward Ahn, Ph.D., CEO and Director, MEDIPOST Inc. cover the realistic applications for AI and automation in process development, visual inspection, data analysis, root-cause analysis, and comparability.

5. Cell Source, Donor Variability, And The Path To Consistency For MSCs 10/2/2026

   In this segment of Cell & Gene Live, Scaling Next-Gen MSC Therapies Without Scaling Risk, Miguel Forte, M.D., Ph.D., CEO and Co-Founder, Kiji Therapeutics, Michael Schuster, Director of Business Development, Mesoblast, and Edward Ahn, Ph.D., CEO and Director, MEDIPOST Inc. explore adult donor-derived, umbilical cord-derived and iPSC-derived MSCs, including donor selection, cell banking and how the starting material can affect manufacturing consistency.

6. Scaling Cryopreservation Without Wasting MSC Product 10/2/2026

   During this segment of Cell & Gene Live, Scaling Next-Gen MSC Therapies Without Scaling Risk, Miguel Forte, M.D., Ph.D., CEO and Co-Founder, Kiji Therapeutics, Michael Schuster, Director of Business Development, Mesoblast, and Edward Ahn, Ph.D., CEO and Director, MEDIPOST Inc. turn the discussion to the practical challenges of cryopreserving large cell volumes, manufacturing capacity, and how companies can avoid introducing major changes as they move toward commercialization.

7. When Small Process Changes Become A Different MSC Product 10/2/2026

   During this final segment of Cell & Gene Live, Scaling Next-Gen MSC Therapies Without Scaling Risk, Miguel Forte, M.D., Ph.D., CEO and Co-Founder, Kiji Therapeutics, Michael Schuster, Director of Business Development, Mesoblast, and Edward Ahn, Ph.D., CEO and Director, MEDIPOST Inc. cover a particularly strong manufacturing point. Even seemingly minor changes in cell culture, processing, or expansion can accumulate and create product drift, raising the question of when a modified process produces what is effectively a different cell therapy.

8. Where AI Can Help MSC Manufacturing 10/2/2026

   In this segment of Cell & Gene Live, Scaling Next-Gen MSC Therapies Without Scaling Risk, Miguel Forte, M.D., Ph.D., CEO and Co-Founder, Kiji Therapeutics, Michael Schuster, Director of Business Development, Mesoblast, and Edward Ahn, Ph.D., CEO and Director, MEDIPOST Inc. cover the realistic applications for AI and automation in process development, visual inspection, data analysis, root-cause analysis, and comparability.

9. Introducing The Next Revolution In Sterile Disconnect Technology 7/20/2026

   Streamline downstream bioprocess teardown with high-flow, non-spill disconnect solutions designed to resist harsh chemicals and protect closed system fluid lines.

10. Streamline Fluid Disconnections And Reduce Tear-Down Complexity 7/5/2026

    Accelerate process turnover and fortify fluid line sterility without complex tools. Gain insight into how modern, metal-free connector geometries mitigate spillage and preserve cell viability.